Mirxes Holding Company Ltd. raised $50 million in a series D funding round to expand its cancer early detection blood tests, including its lead product stomach cancer blood test Gastroclear, in the Asia Pacific region. Mirxes uses RNA technology to develop diagnostic solutions for the early detection of diseases. Read More
Med-tech companies raised $955 million from 40 transactions in July 2023, a decrease of 12.39% from the $1.09 billion raised in July 2022. The volume of med-tech financings has increased from 32 in July 2022, though it is less than the previous six months’ average of 43 and seven-month average of 42. Compared to prior years, July 2021 saw $4.78 billion raised in 74 financings, $3.15 billion from 80 transactions in July 2020 and $1.99 billion from 41 financings in July 2019. Read More
Personadx Inc. and researchers from the University of Chicago Medicine Comprehensive Cancer Center have developed a method to accurately predict which patients with metastatic colorectal cancer will have a favorable treatment outcome following surgical removal of liver metastases, according to a study published in JAMA Oncology. The prognostic tool combines a panel of genetic biomarkers and clinical features of the tumor to determine distinct subgroups of cancer that correspond to different treatment outcomes. Read More
The U.K. National Institute for Health and Care Excellence (NICE) is considering a coverage policy for stenting of the carotid arteries in asymptomatic patients, a change that could give these stents a significantly larger patient population in the U.K. Read More
Results from a meta-analysis of magnetic resonance imaging (MRI)-guided adaptive radiation for prostate cancer by radiation oncologists from the Dana Farber Cancer Institute demonstrated the treatment reduces complications while comparing well to standard approaches. The study was published in Cancer. Read More
U.S. federal government agency recoveries under the False Claims Act (FCA) are down slightly in the first half of 2023 relative to the first half of 2022, but that doesn’t mean companies in the life sciences can afford to let their guard down. The Senate is examining two pieces of legislation that would significantly amplify the risk for device and drug makers, including a Senate bill that would eviscerate the materiality standard as set by the U.S. Supreme Court in Escobar. Read More
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Genedx, Kohlberg, Merit Medical, Pacbio, Tivic. Read More
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Trinity Biotech, Venus Medtech. Read More